Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Use it daily with sunscreen during the day for best results
Stay safe, stay well
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
These are mechanisms associated with the GLP-1 receptor agonist class generally, as documented in the clinical literature
Studies in obesity medicine show that tapering reduces rebound hunger compared to immediate cessation
They are costly
